ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1809

Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis

Philip Mease1, Ana-Maria Orbai2, Oliver FitzGerald3, Mohamed Bedaiwi4, Dona L Fleishaker5, Rajiv Mundayat6, Pamela Young7 and Philip S Helliwell8, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 4Division of Rheumatology, College of Medicine, King Saud University Medical City, Riyadh, Saudi Arabia, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, New York, NY, 7Pfizer Inc, Collegeville, PA, 8Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

Meeting: ACR Convergence 2021

Keywords: Disease Activity, Inflammation, Outcome measures, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Enthesitis (inflammation where the tendon, ligament, or joint capsule insert into the bone) has been associated with higher disease activity and reduced quality of life in patients (pts) with PsA,1 and is therefore recognized as an important domain to consider during treatment.2 Tofacitinib, an oral Janus kinase inhibitor for the treatment of PsA, has been associated with improvements in enthesitis.3, 4 Here, we assessed the effects of tofacitinib on enthesitis by location and severity in pts with active PsA.

Methods: This post hoc analysis pooled data from 2 Phase 3 studies: OPAL Broaden (12 months; NCT01877668)4 and OPAL Beyond (6 months; NCT01882439)3, in pts with active PsA receiving tofacitinib 5 or 10 mg twice daily (BID) or placebo (up to Month [M]3); pts received a stable background dose of a single conventional synthetic DMARD. Enthesitis at baseline (BL) was defined as Leeds Enthesitis Index (LEI)5 > 0 (no enthesitis: BL LEI=0); pts were stratified by BL enthesitis location (for each site, both left and right sides were assessed and results were combined) and severity (LEI site counts: 1/2/3–6 sites). Endpoints (assessed at M1/3/6) included change from BL in LEI score and presence of enthesitis. The proportion of pts without BL enthesitis (LEI=0) developing enthesitis at each location was also assessed.

Results: Data were pooled from 479 pts with LEI > 0 and 227 pts with LEI=0 at BL. For pts with BL LEI > 0, demographics and disease characteristics were generally similar across treatment groups (Table). BL LEI scores across all locations were higher in pts treated with tofacitinib 10 mg BID; BL CRP was higher in pts with 2 affected sites treated with tofacitinib 5 mg BID and in pts with 3–6 affected sites treated with tofacitinib 10 mg BID compared with other treatment groups (Table). Improvements in LEI with tofacitinib were observed as early as M1 and maintained up to M6 across all locations and in pts with greater BL enthesitis severity (≥ 2 sites affected; Figure 1). By M3, fewer pts treated with tofacitinib vs placebo had enthesitis, regardless of BL location or severity (Figure 2a). At M6, the proportion of pts with enthesitis at the specified locations was generally reduced by ~ 50%; similar results were reported for pts with lower BL severity (1 or 2 affected sites; Figure 2a). For pts with high BL disease severity (3–6 affected sites), while the proportion of pts with enthesitis decreased over time from BL, enthesitis was present at M6 in about 2/3 of pts (Figure 2a). By M6, < 13% of pts with BL LEI=0 in each treatment group had developed enthesitis (Figure 2b).

Conclusion: In pts with PsA, tofacitinib treatment resulted in improvements in enthesitis, regardless of location or severity. Therefore, tofacitinib is a treatment option for pts with PsA who have enthesitis.

1. Kaeley GS et al. Semin Arthritis Rheum 2018; 48: 35-43.

2. Coates LC et al. Arthritis Rheumatol 2016; 68: 1060-71.

3. Gladman D et al. N Engl J Med 2017; 377: 1525-36.

4. Mease P et al. N Engl J Med 2017; 377: 1537-50.

5. Healy PJ, PS Helliwell. Arthritis Rheum 2008; 59: 686-91.

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by J Juana, CMC Connect, funded by Pfizer Inc.


Disclosures: P. Mease, AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, 6, Galapagos, 2, 5, Celgene, 2, Boehringer Ingelheim, 2, Genentech, 2, 5, 6, Janssen, 2, 5, 6, Gilead Sciences, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sun Pharma, 2, 5, UCB Pharma, 2, 6, GSK, 2; A. Orbai, AbbVie, 5, Eli Lilly, 2, 5, Celgene, 5, Novartis, 2, 5, Janssen, 2, 5, Horizon, 5, Pfizer, 2, UCB, 2; O. FitzGerald, Novartis, 5, 6, UCB, 5, 6, Pfizer, 5, 6, BMS, 5, 6, AbbVie, 5, 6, Janssen, 5, 6, Lilly, 5, 6, Biogen, 6, Eli Lilly, 5, 6; M. Bedaiwi, AbbVie, 6, Pfizer Inc, 6; D. Fleishaker, Pfizer Inc, 3, 11; R. Mundayat, Pfizer Inc, 3, 11; P. Young, Pfizer Inc, 3, 11; P. Helliwell, Pfizer Inc, 1, Novartis, 6, Janssen, 1, 6, AbbVie, 6, Galapagos, 1, Eli Lilly, 1.

To cite this abstract in AMA style:

Mease P, Orbai A, FitzGerald O, Bedaiwi M, Fleishaker D, Mundayat R, Young P, Helliwell P. Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/efficacy-of-tofacitinib-on-enthesitis-in-patients-with-active-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-tofacitinib-on-enthesitis-in-patients-with-active-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology